Evidence for somatic gene conversion and deletion in bipolar disorder, Crohn's disease, coronary artery disease, hypertension, rheumatoid arthritis, type-1 diabetes, and type-2 diabetes by Ross, Kenneth Andrew
RESEARCH ARTICLE Open Access
Evidence for somatic gene conversion and
deletion in bipolar disorder, Crohn’s disease,
coronary artery disease, hypertension, rheumatoid
arthritis, type-1 diabetes, and type-2 diabetes
Kenneth Andrew Ross
Abstract
Background: During gene conversion, genetic information is transferred unidirectionally between highly
homologous but non-allelic regions of DNA. While germ-line gene conversion has been implicated in the
pathogenesis of some diseases, somatic gene conversion has remained technically difficult to investigate on a
large scale.
Methods: A novel analysis technique is proposed for detecting the signature of somatic gene conversion from
SNP microarray data. The Wellcome Trust Case Control Consortium has gathered SNP microarray data for two
control populations and cohorts for bipolar disorder (BD), cardiovascular disease (CAD), Crohn’s disease (CD),
hypertension (HT), rheumatoid arthritis (RA), type-1 diabetes (T1D) and type-2 diabetes (T2D). Using the new
analysis technique, the seven disease cohorts are analyzed to identify cohort-specific SNPs at which conversion is
predicted. The quality of the predictions is assessed by identifying known disease associations for genes in the
homologous duplicons, and comparing the frequency of such associations with background rates.
Results: Of 28 disease/locus pairs meeting stringent conditions, 22 show various degrees of disease association,
compared with only 8 of 70 in a mock study designed to measure the background association rate (P <1 0
-9).
Additional candidate genes are identified using less stringent filtering conditions. In some cases, somatic deletions
appear likely. RA has a distinctive pattern of events relative to other diseases. Similarities in patterns are apparent
between BD and HT.
Conclusions: The associations derived represent the first evidence that somatic gene conversion could be a
significant causative factor in each of the seven diseases. The specific genes provide potential insights about
disease mechanisms, and are strong candidates for further study. Please see Commentary:
http://www.biomedcentral.com/1741-7015/9/13/abstract.
Background
Gene conversion is a process in which genetic informa-
tion is transferred unidirectionally between highly
homologous but non-allelic regions of DNA [1]. The
genome contains many pairs of homologous regions,
reflecting frequent gene duplication during evolution.
Gene conversion is usually triggered by a double strand
break (DSB), which can occur during meiosis or
mitosis [1]. The DSB is repaired using the homologous
sequence as the template. In mammalian cells, the sister
chromatid is the most frequent conversion substrate [2],
typically leading to perfect repair of a DSB. Gene con-
version from other sequence, however, can lead to DNA
changes. Gene conversion has recently been implicated
in a number of diseases, as a source of both inherited
and de-novo germ-line mutation [1]. It has been
hypothesized that somatic gene conversion is relatively
frequent but has escaped attention due to the technical
difficulty of measurement [1].
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gene, located on the X chromosome. Mutations in IDS
cause Hunter syndrome. There is a pseudogene IDS2
located 20 kb from IDS in an inverted orientation rela-
tive to IDS, with 88% overall homology to IDS [3]. 20%
of Hunter syndrome mutations involve structural rear-
rangements induced by the interaction of the two nonal-
lelic homologous regions [3,4]. The rearrangements
appear to be independent events, indicating a recurrent
mutation rather than common ancestry. Observed rear-
rangements include deletions, inversions, and gene con-
version events [3,4]. Among the regions exhibiting gene
conversion, a complex pattern of alternating sequence
fragments from each of the duplicons is apparent. The
IDS2 pseudogene is missing several IDS exons, but exhi-
bits homology with IDS on each side of this ‘gap’. Some
of the deletion events observed in the IDS gene appear
to represent conversion of IDS sequence by IDS2 in the
vicinity of this gap, leading to the elimination of those
exons [4]. A one kilobase recombinational hotspot has
been identified for the IDS/IDS2 events; this hotspot
exhibits 98% identity compared with the 88% overall
identity of the duplicons [3]. Lagerstedt et al. [3] suggest
that recombination is initiated in this high-identity
region, and spreads through branch migration until a
region of sufficient sequence divergence is reached.
Lagerstedt et al. propose a model in which gene conver-
sion leads to changes in both duplicons, and in which
mismatched base pairs in the heteroduplex DNA may
be corrected to generate additional conversion [3].
Figure 1 illustrates this model. These observations lead
to two important conclusions. First, when looking for
evidence of gene conversion, one should examine all
duplicons for a given sequence. Second, one should
examine the entire contiguous high-homology sequence
in those duplicons, and not limit the analysis to the
immediate neighborhood of a particular locus.
Somatic gene conversion can have multiple kinds of
effects. Most obviously, conversion of a coding sequence
by a non-identical homologous sequence may lead to a
dysfunctional gene product, or an immunogenic novel
amino acid sequence. Conversion of a regulatory, promo-
ter, suppressor, or enhancer sequence may alter gene
expression, either up or down. Since converted sequence
usually retains the methylation status of the source
sequence [5], conversion may result in either the methy-
lation of previously unmethylated promoter sequence,
suppressing gene expression, or in the demethylation of
previously methylated sequence, enabling gene expres-
sion where it was not previously expressed. Gene conver-
sion may also be correlated with other effects of
nonallelic homologous pairing. Crossover and conversion
occur in the same hot spot regions, and gene conversion
appears to be preferred over crossover when interacting
regions are short [6]. Non-allelic crossover may lead to
insertions, deletions and/or inversions. Homologous pair-
ing within a short region of DNA could create DNA loop
structures that alter transcription patterns [7]. Conver-
sion could potentially occur during DNA/RNA pairing
[8,9]. Any of the effects mentioned above could have a
major impact on cell function, and provide plausible cau-
sative mechanisms for disease.
I propose to examine somatic gene conversion in the
context of disease using single nucleotide polymorphism
(SNP) microarray data. Because conversion tracts are
short, linkage disequilibrium (LD) between a gene con-
version locus and nearby SNP markers is likely to be
weak or nonexistent [10]. As a result, it becomes neces-
sary to analyze single-SNP markers without expecting to
see correlated patterns in nearby markers as one would
expect in a traditional disease association study.
The Wellcome Trust Case Control Consortium
(WTCCC) data set was obtained using an Affymetrix
500 K platform [11]. Genotyping was performed on two
large British control populations (58C, NBS), in addition
to disjoint populations for bipolar disorder (BD),
Crohn’s disease (CD), coronary artery disease (CAD),
hypertension (HT), rheumatoid arthritis (RA), type-1
diabetes (T1D) and type-2 diabetes (T2D). The WTCCC
data has been extensively analyzed using a traditional
genomewide association study [11]. This previous analy-
sis required the presence of three concordant SNP mar-
kers in order to identify a disease-associated haplotype.
Such an analysis is likely to miss gene conversion events
because of the weak LD. Further, by focusing the analy-
sis at the called-genotype level, such an analysis is insen-
sitive to somatic changes to the genome.
DNA samples in the WTCCC study are obtained from
lymphocytes. One might be concerned that an analysis
of somatic mutation in lymphocytes may not be infor-
mative about somatic mutation in other tissues more
closely associated with the diseases in the WTCCC
study. Fortunately, there is some evidence that a phe-
nomenon related to gene conversion known as sister
chromatid exchange (SCE) is informative about disease
when measured in lymphocytes. SCE involves crossover
between homologous sister chromatids mediated by the
homologous recombination pathway [12], and has been
interpreted as indicating general genome instability and/
or a response to DNA damage [13]. SCE is elevated in
lymphocytes of individuals with CD [14], CAD [15],
T 1 D[ 1 6 ] ,a n dT 2 D[ 1 7 ] ,b u tn o tR A[ 1 8 ] ,a l t h o u g hi n
some cases the elevation may be related to treatment
rather than disease [19]. SCE is also elevated in multiple
sclerosis [20], systemic lupus erythematosus [21], several
cancers [14], and in individuals with viral infections [22].
Since SCE analysis using lymphocytes (rather than tis-
sues directly affected by the disease) is informative, one
Ross BMC Medicine 2011, 9:12
http://www.biomedcentral.com/1741-7015/9/12
Page 2 of 29might expect lymphocytes to also show disease-asso-
ciated gene conversion behavior. Because blood cells are
widely circulating, they are likely to encounter agents of
double strand breakage such as viruses, and therefore
exhibit gene conversion if conversion is occurring any-
w h e r ei nt h eb o d y .F u r t h e r ,ad i s e a s em a yb ea s s o c i a t e d
with damage to a particular tissue, for example by auto-
immune processes, and the destroyed tissue is unavail-
able for analysis. Other cell types such as lymphocytes
might therefore serve as useful proxies for damaged tis-
sues. If the mechanisms of in-vivo gene conversion are
sequence-specific rather than tissue-specific, then lym-
phocytes would exhibit the same conversion experienced
by the damaged tissue, without eliciting the destruction
response.
To identify somatic changes in a population I propose
a novel data analysis technique. The technique takes
advantage of the fact that a sample contains DNA from
many cells of a single individual. If a significant propor-
tion of those cells have undergone gene conversion at a
locus, then the resulting change in the genotype of
those cells should be measurable as a perturbation in
the intensity for the two allele probes at that locus. An
SNP with a distribution of perturbations specific to a
disease population serves as a marker for a potential dis-
ease-associated locus. More details about how such per-
turbations are measured, and why such perturbations
would have a signature different from other sources of
variation such as paralogous sequence variants, can be
found in the Methods section below.
Once a set of SNPs showing the signature of gene
conversion is identified in a disease population, it would
be desirable to validate those associations using an inde-
pendent source of information that links the disease to
Original sequence (color shows homology with template sequence below)
Homologous (but non-allelic) template sequence
Original sequence experiences double strand break gq p
X
Formation of heteroduplex intermediate
Possible repair outcome
Original
Change in template Change in original Change in original Deletion from original
Template
Change in template
sequence due to 
mismatch repair
Change in original
sequence due to 
mismatch repair
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sequence due to 
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Figure 1 A model of gene conversion between duplicons. Two homologous but non-allelic sequences are shown, with homology indicated
by a common green color. After a double strand break in the original sequence, the template sequence is used to form a heteroduplex DNA
structure with the original sequence during the process of repair. A possible repair outcome is shown, illustrating changes to both the template
and original sequences far from the location of the break, as well as changes and deletion in the original sequence in the vicinity of the break.
Ross BMC Medicine 2011, 9:12
http://www.biomedcentral.com/1741-7015/9/12
Page 3 of 29t h o s eS N P ss i g n i f i c a n t l ym o r ec l o s e l yt h a nt or a n d o m l y
chosen SNPs. As noted above, one needs to consider
not just the SNP locus itself, but all regions with homol-
ogy to the duplicon containing the SNP. The most
direct form of association between a region and a dis-
ease is to find a gene in the region that is known to be
associated with the disease, or that participates in a cri-
tical pathway known to be relevant for the disease.
Additional evidence might include data showing that the
gene is expressed in the relevant tissue with function
related to disease pathogenesis. Most regions of high
homology contain at most a few genes, and so the ana-
lysis can be relatively specific. One could also look for
adjacent genes for which the duplicon could plausibly
contain an upstream enhancer locus. I use 30 kb as a
threshold for this type of adjacency.
When duplicons are nearby on the same chromosome,
the intermediate region between them is an additional
region of interest. Improper recombination between
such regions could lead to inversions, insertions, or
deletions of the intermediate sequence. In some situa-
tions, somatic deletion of a genomic region can generate
patterns similar to those that would be generated by
gene conversion. Deletion might be suspected when the
duplicons occur in an aligned fashion nearby on the
same chromosome, a configuration that could lead to
misaligned recombination.
In the presence of an agent that induces genetic
damage, a cell may respond by inducing the homology-
directed repair pathway [23]. If this pathway is induced
in each of many cells in response to the same agent, the
same homology-biased mutations may happen in a vari-
ety of tissues. Mutations in stem cells will persist in
lineages descending from those cells.
The damage-initiating agent may act locally or glob-
ally. A local agent, such as a virus that damages DNA in
a position-specific manner, could induce gene conver-
sion selectively in the region surrounding the target
sequence. A global agent, such as a deficient or inacti-
vated DNA repair pathway [24], would lead to DNA
damage in a broad (but not necessarily random) fashion,
inducing generalized genec o n v e r s i o na tm a n yl o c i .
Local gene conversion will be identifiable as a perturba-
tion in the disease population that is absent in the con-
trol population and other disease populations.
Perturbations due to global gene conversion may be pre-
sent, to a lesser degree, in other populations whose dis-
eases are caused by global agents. The perturbations
should presumably be absent in the control population
and in populations for diseases caused exclusively by
local agents.
Increased SCE exchange rates are likely to be corre-
lated with a global causative agent. Based on the SCE
data for five of the seven studied diseases [14-18], one
might hypothesize that RA is caused by a local agent,
w h i l eC D ,C A D ,T 1 D ,a n dT 2 Da r ec a u s e db yg l o b a l
agents. This hypothesis will be evaluated in the follow-
ing analysis.
Methods
Raw signal intensity and genotype calling data were
obtained from the WTCCC in an anonymized form, and
the analysis of the data was approved by a Columbia
Institutional Review Board. Each disease cohort con-
tained approximately 2,000 individuals, while the two
control cohorts each contained approximately 1,500
individuals. The Affymetrix platform supports 500,568
SNP loci, of which 459,653 passed the WTCCC quality
control procedures [11].
For a SNP locus with an A/B polymorphism, the
microarray generates a pair of intensity values IA and IB.
Each intensity value is the average intensity over a small
number of oligonucleotide probes containing the allele
together with some flanking sequence. The (IA,I B) point
typically falls within one of three clusters corresponding
to the three genotypes AA, AB, and BB.
Consider now an individual with an AA genotype.
Suppose that 20% of the sampled cells of this individual
have undergone gene conversion in which one of the A
alleles has been converted into a B allele by a homolo-
gous sequence, while the flanking sequence has
remained unchanged. The left example of Figure 2
shows this kind of conversion. (Conversion of both A
alleles would be rare, and is ignored.) This individual
will display an overall (IA ,I B) intensity pair that is 20%
o ft h ew a yf r o mt h eA Ac l u s t e rt ot h eA Bc l u s t e r .I n
another individual with a heterozygous AB genotype, a
20% conversion rate at the same locus would yield an
overall (IA ,I B) intensity pair that is 10% of the way
from the AB cluster to the BB cluster, since only the
conversion of the A allele will cause a change in probe
intensities. In an individual with a BB genotype, no
change would be observed.
Because there is experimental variation in intensity
measurements, it may be difficult to determine whether
a small perturbation in a single measurement represents
gene conversion or merely noise. However, it is possible
to study the distribution of perturbations for a popula-
tion at a locus. If a population has a significant spread
of intensities between clusters, when control populations
do not, then one can hypothesize that gene conversion
at that locus is happening in a population-specific man-
ner. See the cluster plot for RA in Figure 3 for an exam-
ple. If the population is a disease cohort, then the locus
may be associated with the disease phenotype.
Returning to the example above, consider the comple-
mentary situation in which the flanking sequence near
an SNP probe has been converted. Whether or not the
Ross BMC Medicine 2011, 9:12
http://www.biomedcentral.com/1741-7015/9/12
Page 4 of 29SNP locus is changed, the converted sequence will no
longer match either probe sequence. The right example
of Figure 2 shows this kind of conversion. If many cells
in an individual are converted in this fashion, a reduced
signal from this sequence will be measured by both
probes of the microarray. For a locus at which this effect
is associated with the disease phenotype, all clusters will
shift radially towards the origin in the cluster plots for
the disease population.
Calling algorithms attempt to identify the boundaries
of clusters corresponding to the AA, AB and BB geno-
types. For example, the Chiamo algorithm [11], consid-
ers all populations simultaneously, and estimates cluster
boundaries in a way that allows for some population-
dependent differences. The intensity distributions vary
from SNP to SNP, and so clustering is performed sepa-
rately for each SNP.
Based on the analysis above, gene conversion for a
particular population should be accompanied by either
(a) an increase in the spread of the two-dimensional
intensity distribution relative to the control population,
or (b) a translation of the clusters towards the origin,
relative to the control population. In case (a), there
should be an increase in the number of points that are
either between clusters, or on the fringe of a cluster. In
case (b), there should be a decrease in the distance
between clusters, leading to an increase in the number
of points whose cluster assignment is ambiguous. Either
way, there will be an increase in the number of no-calls
generated by the calling algorithm, relative to the con-
trol populations. This is one ‘signature’ of gene conver-
sion that I will try to identify.
The Chiamo calling algorithm has been applied to the
WTCCC data, and it is possible to use those calls to
help recognize the signature of gene conversion. Chiamo
generates a confidence scoref o rac a l l ;t h ea u t h o r so f
the Chiamo algorithm recommend that when this score
is below 0.9, the genotype should be considered a ‘no-
call.’ When clusters are more dispersed, their peripheries
can begin to overlap with each other. In such a situa-
tion, the Chiamo algorithm will have less certainty
about points falling in the intermediate regions. Chiamo
SNP probe sequences (25bp, color shows homology)
All l A Allele A
Allele B
SNP locus sequences (in an AA homozygote)
Strand 1
Strand 2
Duplicon sequence (non-polymorphic) pq ( py p )
Case 1, flanking sequence matches probe Case 2, flanking sequence does not match probe




St d 2 Strand2
lower A signal, higher B signal
Strand2
lower A signal, unchanged B signal
Figure 2 Effects of gene conversion on probe intensity signals. A microarray has two probes for a SNP, each 25 bp long (top). An individual
with an AA homozygous genotype at the SNP locus is shown. Two examples of gene conversion are illustrated. The left example considers the
case when the duplicon contains sequence that exactly matches the B probe. The right example considers the case when the duplicon contains
sequence that does not match either probe.
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an increase in the no-call rate for intermediate points
[11]. An example of this phenomenon is given in Figure
3, where the orange points (that are particularly fre-
quent in RA at this locus) are no-calls.
An increase in no-calls between two clusters can lead
to a biased allele distribution in the called genotypes.
For example, if there are many no-calls between the AA
and AB clusters, then the A allele will be underrepre-
sented among the subpopulation whose genotypes are
called with high confidence. This bias is another possi-
ble signature for gene conversion. (See Additional file 1
for an extended discussion of no-calls.) Note that there
may be cases of gene conversion that do not show this
signature because the non-called points do not change
the observed allele frequencies.
To identify gene conversion events, I take three com-
plementary approaches. The first approach that I call
the ‘stringent’ filter is designed to optimize precision,
that is, to minimize the number of false positives while
possibly missing some true positives. The second
approach is designed to provide better recall, that is, to
include more true positives at the risk of also including
false positives. This second approach is called the
‘relaxed’ filter. The third approach, termed the ‘no-call-
only’ filter, looks only for extreme no-call rates, since





Figure 3 Cluster plots for SNP rs4988327 in the WTCCC data. Note the high spread for RA, and the resulting increase in no-calls (orange)
relative to calls (green).
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rates in a population relative to the union of the two
control populations are initially selected. A chi-squared
statistic is calculated for each SNP based on a 2 × 2 chi-
squared test comparing calls/no-calls for both the
disease population and the control population. Only
SNPs with an increase in the no-call rate in the disease
population and a chi-squared statistic corresponding to
P <5×1 0
-5 in a one-sided test are retained by this
initial selection.
A further selection is applied to test for a bias in the
genotype distribution in the disease population relative
to controls. Bias is assessed in one of two ways; an SNP
that displays bias according to either of these tests is
retained. Only SNPs in which the control population
has at least ten individuals for each of the AA, AB and
BB genotypes are considered. First, the three genotype
frequencies in the disease population are compared with
the corresponding frequencies in the control population
using a 3 × 2 chi-squared test to determine the likeli-
hood that they have a common distribution. Only SNPs
with a chi-squared statistic corresponding to P <5×
10
-4 in a two-sided test are retained. Second, the three
genotype frequencies in the disease population and con-
trol population are separately assessed for departure
from Hardy-Weinberg Equilibrium using a conventional
3×2c h i - s q u a r e dt e s t .O n l yS N P sw i t hac h i - s q u a r e d
statistic corresponding to P <5×1 0
-4 in a two-sided
test in the disease population and a chi-squared statistic
corresponding to P > 0.01 in the control population are
retained.
Gene conversion appears to require at least 300 base
pairs of homology in humans [1]. Among known gene
conversion loci, the smallest degree of identity between
the homologous regions is 88% [1]. One should there-
fore not expect newly discovered loci to have identity
much below 88%. I will thus use 85% identity as a lower
bound for the stringent filter.
The candidate SNPs were evaluated for homologous
flanking sequence elsewhere in the genome. The UCSC
database of segmental duplications [25] was used to
identify genomewide duplications with at least 1,000
base pairs of homology (after elimination of low-
complexity repeats) and at least 90% identity. Addition-
ally, each SNP that met the other stringent filter condi-
tions was subjected to manual analysis using the BLAST
network service at NCBI to identify duplications that
may not meet the thresholds of the segmental duplica-
tion database, but that may still be relevant for gene
conversion. (I used the Megablast algorithm with default
parameters. When a duplicon contains several almost-
contiguous segments, the identity of the duplicon is the
identity reported by BLAST for the segment containing
the region that maps to the SNP under consideration.)
The three filters are summarized in Table 1. The relaxed
and no-call filters use different homology criteria from
the stringent test so that the segmental duplication data-
base can be used to automate the analysis. Because the
segmental duplication database excludes regions with
low complexity repeats, some SNPs in regions with
more than 90% homology (for example, rs9378249) are
not in the segmental duplication database.
The analysis does not consider SNPs on the Y chro-
mosome. For the X chromosome, the analysis is limited
to the female subpopulation within each cohort. As a
result, some statistical power is lost, particularly for
cohorts such as CAD that have a relatively small num-
ber of female members.
Cluster plots for all SNPs mentioned in the text can
be found in Additional file 2.
Sources of variation
Copy number variations at an SNP locus mean that in
addition to the conventional AA, AB, and BB genotypes,
there may be additional genotypes such as AAB and B.
Each of these alternative genotypes would have its own
cluster in the cluster plot, which can be examined for
signs of more than three clusters. Each SNP was also
assessed for known copy-number variation using the
Database of Genomic Variants [26], since copy-number
variants could also cause changes in no-call frequencies
and genotype distributions that may be related to dis-
ease. (See Additional file 1 for further discussion of copy
number variation.) Note that somatic deletion would
generate genotypes like B in some cells, but since most
cells retain the normal copy number, the effect will be a
small perturbation in the cluster plot rather than a sepa-
rate cluster. Germ-line mutations would not give the
same perturbation patterns as somatic conversion. For a
germ-line mutation that changed one allele to another,
the individual would appear as part of another cluster in
the corresponding cluster plot. If a germ-line mutation
deleted or duplicated an allele, then the individual
would appear as part of a cluster with a nonstandard
copy number. If this deletion/duplication was common,
then the cluster plot would show features typical of
CNV loci, such as the presence of more than three
clusters.
A paralogous sequence variant occurs when the
homologous sequence to the mapped SNP sequence





Stringent P <5×1 0
-5 300 bp, 85% P <5×1 0
-4
Relaxed P <5×1 0
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-2
No-call only P <1×1 0
-8 1,000 bp, 90% -
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for alleles A and B. If the paralogous sequence also has
an A/B polymorphism, then the cluster plot will have
five clusters, corresponding to AAAA, AAAB, AABB,
ABBB, and BBBB. If the paralogous sequence has an
A/C polymorphism, then the probes will not detect the
signal from the C allele, and there will be clusters for
AA, AB, BB, AAA, AAB, ABB, AAAA, AAAB, AABB. In
either case, the cluster plot will differ significantly from
what is expected under a gene conversion hypothesis.
Some polymorphisms on the microarray platform may
have been misidentified, with the true polymorphism
being in paralogous sequence with no polymorphism at
the mapped SNP locus. As long as the paralogous
sequence is part of a larger region of homology with the
mapped SNP locus, the outcome of the gene conversion
analysis will be unchanged by such phenomena because
both duplicons are examined.
A foundational somatic mutation could occur during
early development, leading to a lineage of cells within
the individual carrying the mutation. This kind of muta-
tion will not be identified by the present analysis unless
the blood cells being genotyped come from more than
one such lineage. Even then, the relevance of a founda-
tional mutation to disease would be unclear because the
mutation would also have to have been in a lineage
ancestral to the diseased tissue.
Results
Putative gene conversion events detected using the
stringent filter
31 instances of putative gene conversion with duplicon
identity of at least 85% were identified using the strin-
gent filter, covering 23 distinct SNPs. This data is sum-
marized in Tables 2, 3 and 4; additional information
about the associations can be found in Table S1 in
Additional file 1. The SNPs in Table 4 fall within the
MHC region and are identified by the stringent filter for
T1D. Since T1D has significant associations at the hap-
lotype level in the MHC region [11], it is difficult to
separate a conversion signal from the broader associa-
tion signal for these SNPs. The same is true for RA
[11], but no MHC SNPs were identified for RA using
the stringent filter.
In all 28 of the 28 instances in Tables 2 and 3, the
change in allele frequency is consistent with what would
be predicted by a gene conversion hypothesis (see Addi-
tional file 1). Additional SNPs that met the stringent fil-
ter conditions except that identity between duplicons
was 71%-83% are discussed in Additional file 1.
The strength of the evidence for a putative SNP/dis-
ease association is determined by consulting the pub-
lished literature in search of a known association. The
strength of the evidence is summarized using the scale
of Table 5, where a higher number corresponds roughly
to stronger evidence. The score for a SNP is the maxi-
mum score for any gene in any duplicon associated with
the SNP; genes for which a duplicon occurs 30 kb or
less upstream of the gene are included. Note that the
score for an SNP does not give any weight to genes
occurring between neighboring homologous regions
(except for the 30 kb-upstream genes mentioned above).
The evidence score therefore ignores the possible dele-
tion and/or duplication of genes in the intervening
sequence. The code for the strength of the evidence is
given in parentheses in the heading for each SNP.
To assess the significance of the set of identified
regions, the duplicons for the SNPs identified by the
stringent test (which should have few false positives) are
assessed for association with the corresponding disease.
The code for the strength of the evidence is given in
parentheses in the heading.
rs4471699 in CD (6)
Of the characterized genes in the various duplicons,
SULT1A3 has the most obvious connection to the CD
phenotype involving inflammation of the small and/or
large intestine. SULT1A3 is highly expressed in the
small intestine [27] where it specifically sulfates dopa-
mine and is important for the metabolism of several
neurotransmitters [28]. SULT1A3 shows reduced
expression in the colons of CD patients [29]. (The
related genes SULT1A1 and SULT1A2, which are also
located in a segmentally duplicated region of chromo-
some 16, have reduced expression in CD [30].) Eisenho-
fer et al. [28] suggest that the production of dopamine
sulfate in the intestine ‘reflects an enzymatic “gut-blood”
barrier for detoxifying dietary biogenic amines.’ Dys-
function of this pathway could lead to toxicity in the
small and large intestines.
T h eU Q C R C 2g e n ei sap a r to ft h em i t o c h o n d r i a l
respiratory complex III. Apolipoprotein E4 binds to
UQCRC2, and overexpression of a fragment of this pro-
tein impairs the function of complex III [31]. Mitochon-
drial dysfunction has been associated with CD in several
case reports, including one with dysfunction in complex
III [32].
Strikingly, the duplicon containing rs4471699 and the
closest matching duplicon have recently been shown to
be endpoints of a region deleted in the germ-line in cer-
tain cases of autism, and duplicated in others [33,34].
Among the common features of autism are gastrointest-
inal abnormalities [35]. Mitochondrial dysfunction also
occurs with increased frequency in autism [36,37].
rs669980 in RA (5)
CBWD1 (and by inference also CBWD2) has 25% pro-
tein identity with the cobW gene of P. dentrificans
that is thought to be involved in vitamin B12 proces-
sing [38], and possibly cobalt chelation [39,40].
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vium of RA patients [41,42]. Low serum vitamin B12
levels are noted in a significant percentage of RA
patients [43]. Methyl B12 appears to suppress cytokine
production in T lymphocytes [44], which may be
relevant to RA. Improper vitamin B12 processing can
lead to elevated plasma homocysteine levels, which has
been observed in multiple RA cohorts [45].
Dysregulation of cobalt chelation could also have sec-
ondary mutagenic effects, since cobalt is genotoxic [46].









CD rs4471699 16: 30.2 M® 147 kb SULT1A3, GIYD2, BOLA2, IMAA, CORO1A
99.6% 16: 29.4 M® 146 kb SULT1A3, GIYD2, BOLA2, IMAA, MLAS
98.1% 16: 21.8 M® 41 kb [UQCRC2]
98.0% 16: 22.3 M¬ 42 kb [NPIPL3]
98.0% 16: 21.3 M® 42 kb IMAA, [NPIPL3]
97.1% 16: 18.8 M® 75 kb SMG1
RA rs669980 9: 0.2 M® 193 kb CBWD1, FOXD4, FAM138A, WASH1, [DOCK8]
98.9% (F) 2: 114 M¬ 189 kb CBWD2, FOX4DL1, FAM138B, WASH2P, [RABL2A]
CAD, T2D rs10502407 18: 10.6 M® 52 kb -
97.9% 18: 12.2 M¬ 64 kb [CIDEA]
CAD rs12134625 1: 78 M® 931 -
97.0% 1: 24 M¬ 932 FUSIP1
BD, CAD rs9551988 13: 19.2 M® 2.6 kb PSPC1
HT 96.2% (F) 13: 18.7 M® 2.8 kb [TUBA3C]
HT rs935019 2: 127,162 K® 3.6 kb GYPC
95.3% (F) 2: 127,166 K® 3.5 kb GYPC
HT rs12227938 12: 37 M® 154 kb ALG10B
95.3% (P) 12: 34 M® 127 kb ALG10
T2D SNP_A-1797773 16: 45 M® 14 kb VPS35, [ORC6L]
94.8% (F) 16: 34 M¬ 16 kb -
T1D rs12381130 16: 5 M® 88 kb ALG1, FAM86A
94.7% 3: 127 M¬ 76 kb ALG1L
94.6% 11: 67 M® 79 kb -
94.6% 11: 71 M¬ 40 kb FAM86C, [DEFB108B]
94.5% 11: 3 M® 91 kb [ZNF195]
94.3% 3: 76 M® 44 kb [FAM86D]
94.0% 4: 9 M¬ 120 kb -
93.9% 3: 131 M® 44 kb -
93.9% 4: 4 M® 53 kb -
93.7% 12: 8 M® 53 kb [FAM90A1]
93.6% 8: 12 M® 41 kb [FAM86B1]
93.5% 8: 8 M¬ 63 kb -
Multiple almost-contiguous segmental duplications are treated as a single large duplicon (intervening sequence is included in the length). The table includes only
duplicons with at least 85% identity to the region containing the SNP. Duplicons with identical flanking sequence to the SNP are labeled as fully degenerate (F);
duplicons with partial degeneracy are labeled (P). Characterized genes are listed if they occur within a duplicon. Genes in square brackets are outside the
duplicon, but the duplicon is at most 30 kb upstream of the gene. Genes for a SNP are italicized if the SNP is within that gene, or if the SNP maps to a position
within that gene in the duplicon.
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CD rs11060028 12: 128 M® 1.5 kb GLT1D1
93.4% (P) 10: 102 M¬ 1.2 kb [ABCC2]
T1D rs3805006 3: 4,775 K® 402 ITPR1, [EGO]
93.4% (P) 3: 4,773 K¬ 407 ITPR1, [EGO]
BD, HT rs9378249 6: 31.4 M® 27 kb HLA-B, DHFRP2
92.9% (F) 6: 31.3 M® 35 kb HLA-C
HT rs841245 12: 27.1 M® 84 kb -
92.0% (P) 12: 27.6 M® 82 kb PPFIBP1
BD rs12070036 1: 224 M® 9k b ZNF678
91.9% 12: 7 M¬ 3.5 kb [PEX5]
91.1% 12: 123 M¬ 10 kb [RILPL1], [TMED2]
90.9% 11: 26 M¬ 2.7 kb -
RA rs4988327 11: 68 M® 104 kb LRP5
91.2% 22: 24 M¬ 64 kb LRP5L
T2D rs11010908 10: 37.2 M® 6k b -
90.6% 10: 27.2 M¬ 12 kb -
90.0% 10: 27.6 M® 6k b -
CAD rs295470 3: 141 M® 1.9 kb ACTGP1, [RBP2]
89.5% 17: 77 M¬ 2.3 kb ACTG1, [FSCN2]
89.1% 1: 92 M¬ 866 -
87.8% X: 53 M¬ 636 -
86.6% 2: 108 M® 568 -
86.5% 17: 17 M® 696 [FLCN]
85.9% 3: 12 M® 1.9 kb SYN2
BD, HT rs2122231 3: 35 M® 4.9 kb -
88.8% 6: 117.0 M® 4 kb [NT5DC1]
88.6% 18: 5 M® 3.9 kb -
88.5% 2: 194 M® 1k b -
87.9% 1: 96 M® 4.9 kb -
87.3% 10: 117 M® 4.2 kb -
86.3% 20: 24 M® 728 -
BD, HT SNP_A-1948953 17: 17 M® 894 LNX1 pseudogene LOC644909
87.0% (P) 4: 54 M¬ 21 kb LNX1
CD rs9839841 3: 16 M® 110 kb RFTN1
86.8% (F) Y: 7.6 M® 100 kb RFTN1-pseudogene LOC360015, [TTTY12], [TTTY16]
BD, T2D rs4850057 2: 4 M® 4.7 kb -
86.8% 9: 35 M® 4.5 kb UNC13B
86.1% 11: 5 M® 3.0 kb [TRIM68], [OR51D1], [OR51E1]
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CIDEA has known associations to obesity, insulin resis-
tance, and T2D [47-49], which are also risk factors for
CAD [50]. The duplicon is located upstream of CIDEA
in a potential enhancer locus.
rs12134625 in CAD (3)
The FUSIP1 gene specifically represses splicing during
mitosis [51,52] and in cells subject to heat shock [53].
Cells lacking FUSIP1 are defective in recovery after heat
shock [53]. Splice repression after heat shock prevents
the possible accumulation of inaccurately spliced
mRNAs, until the heat-damaged splicing apparatus is
restored to normal [53]. FUSIP1-null mice display multi-
ple cardiac defects during embryonic development, due
to improper processing of pre-mRNA encoding cardiac
triadin [54]. Somatic defects in FUSIP1 that lead to mis-
spliced triadin transcripts could be a pathogenic
mechanism in CAD.
rs9551988 in CAD (3), BD (3), HT (3)
PSPC1 has sequence-specific RNA-binding domains, and
localizes to paraspeckles [55]. While the function of
paraspeckles is not fully understood, Prasanth et al. [56]
describe how paraspeckles store CTN-RNA, which is
cleaved under conditions of stress and released
for immediate translation into protein. Prasanth et al.
argue that this mechanism allows the cell to provide a
rapid stress response, rather than having to wait for
RNA transcription [56]. The released mRNA encodes
S L C 7 A 2 ,a l s ok n o w na sC A T 2 ,ac a t i o n i ca m i n oa c i d
transporter involved in L-arginine transport, a necessary
step in nitric oxide (NO) synthesis [56,57]. Insulin
directly effects vascular endothelium and smooth muscle
via nitric oxide release [58,59]. The pathway for insulin-
induced NO synthesis involves L-arginine transport and
the SLC7A2 gene [58,60,61]. The physiological implica-
tions of a dysregulation of insulin in obesity, CAD, and
HT are well known [58,59]. A dysregulation of SLC7A2
function could have similar effects. In preeclampsia (HT
and proteinuria in pregnancy) the L-arginine NO system
of circulating leukocytes appears dysregulated [62]. The
L-arginine NO pathway appears to be involved in the
pathogenesis of BD [63,64].
rs935019 in HT (4)
The two duplicons are immediately adjacent and aligned
within the GYPC gene. Such an arrangement provides
an opportunity for improper recombination due to mis-
alignment. Indeed, deletion variants of the GYPC gene
have been attributed to unequal crossover at these
duplicons [65]. One of these deletions frequently occurs
spontaneously in E. coli during cloning [65], suggesting
that spontaneous somatic deletions are also likely.
The GYPC gene codes for the GPC and GPD proteins,
which regulate the shape and mechanical properties of
red blood cells [66]. While there is no direct evidence
linking GYPC to HT, the tissue-specificity and function
of GYPC make such a link plausible.
rs12227938 in HT (3)
The HERG gene encodes pore-forming alpha-subunit
protein important for repolarizing K
+ current in the









T1D rs9378249 6: 31.4 M® 27 kb HLA-B, DHFRP2
92.9% (F) 6: 31.3 M® 35 kb HLA-C
T1D rs9257223 6: 29 M® 16 kb -
92.5% 11: 50 M® 16 kb -
T1D rs389600 6: 30 M® 4 kb HLA-K
87.5% 6: 30 M¬ 4 kb HLA-A
87.5% 6: 30 M¬ 4 kb HLA-H
86.2% 6: 30 M¬ 4 kb HLA-J
85.8% 6: 30 M¬ 3.5 kb HLA-G
Table 5 Numeric codes describing the strength of
evidence for an association of a gene with a disease
Code Kind of evidence
6 Known association of the gene with the disease.
5 Gene is known to interact with an intermediate, and the
intermediate has a known association with the disease.
4 Known association of the gene with a function central to
disease pathogenesis (for example, insulin secretion for
diabetes).
3 Gene is known to interact with an intermediate, and the
intermediate has a known association with a function central to
disease pathogenesis.
2 Known association of a region containing the gene with the
disease.
1 Gene disruption is known to have a general mutagenic effect.
0 No evidence.
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modulates HERG, reducing the sensitivity of cardiac
cells to arrhythmic disturbance [68,69]. ALG10B sup-
presses heart rhythm and regulates cardiac automaticity
[70]. Polymorphisms on ALG10B are associated with the
risk of acquired long QT syndrome, a cardiac rhythm
disturbance [71]. Somatic defects in ALG10B would
have direct relevance to HT.
SNP A-1797773 in T2D (4)
VPS35 is part of the retromer protein complex, which
has a variety of sorting-related functions [72]. Mutant
VPS35 is associated with improper insulin secretion
[73].
rs12381130 in T1D (0)
This particular duplicon has homology with many other
regions. Interestingly, on c h r o m o s o m e s3 ,4 ,8 ,a n d1 1
there are pairs of homologous duplicons about 4 Mb
apart. Gene conversion at rs12381130 could be a marker
of more general conversion and/or improper recombina-
tion at these locations, potentially leading to somatic
deletions, duplications or inversions of the sequence
between duplicon pairs on a chromosome.
rs11060028 in CD (6)
GLT1D1 appears to be a glycosyltransferase, but rela-
tively little is known about its specific function. The
chromosome 10 duplicon is 16 kb upstream of ABCC2
in a possible enhancer locus. ABCC2 is expressed on
the apical membrane in the jejunum, ileum and colon
[74]. It is an efflux transporter, responsible for extruding
toxic substances from the cell [29,74]. ABCC2 expres-
sion is reduced in CD, in both the ileum and colon [29].
rs3805006 in T1D (4)
rs3805006 is located within an intron of ITPR1, and 7
kb upstream of the noncoding RNA gene EGO [75].
ITPR1, together with the related receptors ITPR2 and
ITPR3, regulate calcium release within the insulin secre-
tion pathway in pancreatic beta cells [76]. The ITPR3
gene was associated with T1D in a Swedish population
[77], although see [78,79].
rs9378249 in BD (0) and HT (0)
This SNP falls within the MHC region on chromosome
6. There is no general association of the MHC region
with either BD or HT in the WTCCC data [11],
although the region has recently been implicated in
schizophrenia [80].
In the cluster plots for rs9378249, the no-calls for BD,
HT, and T1D are located in the middle of the heterozy-
gote cluster. This kind of clustering pattern strongly
suggests variation between populations in the magnitude
of the intensity measurements. Intensity variations could
be a result of either somatic gene conversion or somatic
deletion in certain populations, assuming in both cases
that the control populations have higher intensity than
the affected populations.
A diagram of the homology between the two dupli-
cons is given in Figure 4. From this diagram, it becomes
apparent that conversion of the lower region by the
upper region could eliminate the DHFRP2 sequence
entirely.
Relatively low raw intensity levels at a locus would be
expected if there were a significant number of deletions
at that locus in somatic cells. Low intensity at
rs7761068, which resides in the putatively deleted region
and is the closest SNP to DHFRP2 in the microarray
data set, could be interpreted as an indicator of more
frequent somatic deletion of the region containing
DHFRP2.
To determine a threshold for low/high intensity at
rs7761068, the two control populations were pooled and
the three genotype clusters were analyzed separately.
For the first homozygous cluster, which is close to the
y-axis in the cluster plot, the median y-intensity is
1.227. For the second homozygous cluster, which is
close to the x-axis in the cluster plot, the median
x-intensity is 1.493. For the heterozygous cluster, the
median (x + y)-intensity is 1.888. Based on these num-
bers, an individual is defined to have low intensity at
rs7761068 if the x, y, and x + y values are all lower than
the corresponding thresholds; otherwise the individual is
said to have high intensity at rs7761068. Each of the
populations was then partitioned into low and high
intensity fractions.
The results shown in Figure 5 strongly suggest that
there is increased deletion in all disease populations
besides RA. (A 2 × 2 chi-squared test comparing each
population with the combined controls yields P =0 . 0 2
for CD, and P <1 0
-13 for the other fivep o p u l a t i o n s . )
rs9378249 displays an intensity distribution with features
similar to rs7761068 shown in Figure 5, suggesting that
deletion due to conversion and/or deletion of the green
regions is more likely to be responsible than interactions
between the pink region containing DHFRP2 and the
region containing DHFR.
DHFRP2 is a pseudogene with homology to DHFR.
DHFR codes for dihydrofolate reductase, an enzyme
required for the synthesis of thymine nucleotides.
Impaired T synthesis causes misincorporation of uracil
into DNA, leading to various kinds of DNA damage
[81]. While DHFRP2 is noncoding, its mRNA could
interact with DHFR mRNA via an antisense regulatory
mechanism [82]. The DHFR gene locus shows evidence
of both sense and antisense transcription [83], consistent
with a role for antisense regulation. (Since interactions
of DHFRP2 and DHFR have not been demonstrated, the
evidence level of this hypothesis is zero.)
In BD patients, folate sensitive fragile sites are
expressed more often than in controls [84]. Polymorph-
isms in the MTHFD1 gene, which encodes several folate
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Figure 5 Proportion of each of the nine populations having low measured intensity at rs7761068. The intensity thresholds were chosen








Figure 4 The structure of the homology between the HLA-B and HLA-C containing duplicons on chromosome 6. Genes and
pseudogenes are shown in blue. Corresponding homologous regions are shown in matching shades of green, together with the degree of
homology according to the segmental duplication track of the UCSC browser (the two rightmost segments) or Blast (the leftmost segment). The
pink region is about 91% homologous to the DHFR region on chromosome 5.
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Page 13 of 29enzymes, are associated with BD [85]. Polymorphisms in
the MTHFR gene, which encodes 5,10-methylenetetra-
hydrofolate reductase, have been associated with HT
[86] and BD [87]. High homocysteine levels, which are
often associated with folate deficiency, are associated
with hypertension [88], and folate supplementation
appears to decrease the risk of developing HT [89].
rs841245 in HT (5)
PPFIBP1 encodes the liprin-beta-1 gene, which is highly
expressed in the heart [90]. Liprin-beta-1 interacts speci-
fically with the S100A4/Mts1 protein in vivo [91]. The
S100A4/Mts1 protein is more highly expressed in indivi-
duals with HT, and appears to cause changes in vascula-
ture [92-95].
rs12070036 in BD (5)
ZNF678 has unknown function. It has diverged signifi-
cantly from all other known zinc-finger proteins [96],
and is associated with human variation in height [97].
The chromosome 12 duplicon at 7.2 Mb is located
3.3 kb upstream of PEX5 in a potential promoter
region. PEX5 is a gene responsible for recognizing PTS
proteins in the peroxisome [98]. Defects in PEX5 cause
one of several peroxisome biogenesis disorders, accom-
panied by reduced plasmalogen biosynthesis in the
brain [99,100]. Plasmalogen is a lipid that is abundant
in myelin, and peroxisome dysfunction leads to demye-
lination and axon degeneration in the central nervous
system [101]. Somatic mutations in a PEX5 promoter
could lead to situations in which some neurons are
myelin-deficient, causing aberrant signaling. Demyeli-
nation has been previously suggested as a pathogenic
mechanism in BD [102], and an association between
BD and multiple sclerosis (a demyelinating disease)
have been observed [103,104]. Valproate treatment for
BD appears to change the behavior of the peroxisome
in neurons [105].
rs4988327 in RA (6)
The scatter plot for this SNP is shown in Figure 3.
LRP5 is a member of the canonical WNT5a signaling
pathway that is initiated by IL6 in rheumatoid synovial
fibroblasts [106]. LRP5 is also associated with bone
mineral density and with susceptibility to osteoarthritis
[107,108].
rs11010908 in T2D (0)
While there are no characterized genes in the duplicons,
two of the duplicons are adjacent, spanning a 370 kb
region that includes the genes ANKRD26, YME1L1,
MASTL, and ACBD5. ANKRD26-knockout mice
develop hyperphagia-induced obesity and insulin resis-
tance [109], as might be expected for a gene associated
with T2D.
rs295470 in CAD (5)
The function of ACTG1 appears to be the maintenance
of the actin cytoskeleton [110]. A muscle-specific
ACTG1-knockout leads to progressive myopathy [111].
Conversely, injection of a human ACTG1 construct (but
not constructs based on ACTC1 or ACTG2) into adult
rat cardiomyocytes caused a cessation of beating, sug-
gesting a dominant negative effect of overexpression of
ACTG1 [112]. ACTG1 appears to play an important
role in the structure and normal function of striated
muscle [111,113].
RBP2 cDNA is down-regulated by low density lipopro-
tein, which may be relevant to CAD [114]. RBP2 partici-
pates in the uptake and/or metabolism of vitamin A,
which is converted to retinol. Low plasma retinol is
associated with coronary events [115].
rs2122231 in BD (0) and HT (0)
rs2122231 is located within a region of human ERV9
retroviral sequence. Gene conversion between this
sequence and other ERV9 sequence could change ERV9
expression behavior. Variation in ERV9 expression has
been associated with psychiatric disorders, including BD
and schizophrenia [116,117].
ERV9 long terminal repeat (LTR) sequence also
appears in the promoter of the beta globin gene [118].
Disruptions of ERV9 expression could affect beta globin
transcription, providing a plausible link to HT. There
are many ERV9 LTR sequences in the human genome;
in the absence of evidence that this particular region is
responsible for ERV9 expression, the evidence level for
these associations is 0.
SNP_A-1948953 in HT (3) and BD (3)
LNX proteins including LNX1 interact with members of
the Notch signaling pathway that could affect the forma-
tion of neuronal cell shape and synaptic connections in
the brain [119]. LNX1 interacts with CAST in neurons,
and CAST is associated with neurotransmitter release
[120]. These properties of LNX1 may be relevant for
BD.
LNX1 binds with CXADR, the coxsackievirus and ade-
novirus receptor [121]. Coxsackievirus seroprevalence
has been associated with HT [122].
Interestingly, LNX1 RNA is a much closer match to
the SNP_A-1948953 duplicon than the LNX1 DNA;
there are gaps in homology that coincide with the LNX1
introns.
rs9839841 in CD (4)
The duplicon for this SNP is on the Y-chromosome, sug-
g e s t i n gt h a tg e n ec o n v e r s i o ns h o u l db eo b s e r v e do n l yi n
males. The rs9839841 SNP is a C/T polymorphism on
chromosome 3. The corresponding Y-chromosome locus
has a 35 bp flanking sequence that is identical to the
chromosome 3 sequence containing the T allele. As a
result, the microarray will show a base intensity for the T
allele that is higher in males than in females. One should
thus interpret the scatter plots and clustering results with
caution, as they may be influenced by the relative
Ross BMC Medicine 2011, 9:12
http://www.biomedcentral.com/1741-7015/9/12
Page 14 of 29frequency of each gender in the population. In support of
at r u eC Da s s o c i a t i o na tt h i sl o c u sf o rm a l e s ,F i g u r e6
shows a scatter plot limited to males for the CD, 58C and
NBS populations. The CD population shows a higher
spread despite having approximately the same number of
data points as each control population.
RFTN1 modulates T-cell signals, particularly Th17,
and influences the severity of autoimmune responses
[123]. RFTN1 is also needed for B-cell receptor signal
transduction [124]. CD and some other chronic inflam-
matory diseases are mediated by Th17 cells [125,126].
rs4850057 in T2D (6) and BD (4)
UNC13B expression is reduced in pancreatic beta cells
of rat models of T2D [127]. Conversely, overexpression
of UNC13B amplifies insulin exocytosis [127]. These
results are directly relevant to T2D in which insulin
exocytosis is dysregulated [128,129].
UNC13B also modulates neurotransmitter release in
neurons [130-132], a pathway relevant for BD.
The HLA region in T1D
It is difficult to separate a conversion signal from the
broader association signal for T1D in the MHC region;
the MHC region on chromosome 6 has extensive asso-
ciation with T1D [11]. Recent high resolution studies
have identified an association signal at the HLA-B
locus (but not the HLA-C locus) that is independent
of the MHC class-II loci [79]. HLA-C has been linked
with T1D when considered in combination with KIR
genes that are expressed in natural killer cells
[133,134].
T h e r ea r em a n yp l a u s i b l ew a y st h a td i s r u p t i o no fa n
immunity-related gene could modulate T1D pathogenesis.
Gene conversion provides additional candidate hypoth-
eses. For example, gene conversion in the duplicons asso-
ciated with rs389600 could lead to disruption of HLA-G
expression. HLA-G expression is immunoprotective in
pancreatic islets [135]. An association between the HLA-G
region and T1D has previously been observed [136].
Significance of stringent test associations
The ways that the identified genes appear to be relevant to
the corresponding disease are diverse. This diversity
makes it difficult to formally quantify the significance of
the noted associations. In particular, it might be that any
sample of genes from duplicated regions leads to many
associations with disease pathways if the literature is
examined to sufficient depth. To eliminate this possibility,
and to quantify the degree of ‘background’ association one
would expect, I conducted a mock association study.
In the mock study, I identified ten SNPs for each dis-
ease. The SNPs were chosen to reside on known seg-
mental duplications from the segmental duplication
database. A chi-squared statistic comparing the distribu-
tions of AA/AB/BB genotypes in controls and in the dis-
ease samples was computed, and the ten SNPs that
minimized this statistic were chosen. (The selected
SNPs for a disease sample are therefore those whose
genotype distributions are closest to the controls.) For
each disease I searched for disease associations using
the literature in the same way that associations were
sought for SNPs selected by the various filters. The
details are presented in Tables S15 and S16 in Addi-
tional file 1.
The hypothesis being tested is that the associations of
the stringent test and the mock test differ in the degree
of association to the corresponding disease. The rate at
which known evidence was found in the stringent test
and the mock study is summarized in Table 6. SNPs in
the MHC region for T1D were excluded. A Fisher’s
exact test of the difference between the stringent filter
and mock study at evidence level three gives P <1 0
-9.
Even if one limits the stringent test results to SNPs
CD 58C NBS
Figure 6 Cluster plot for males at the rs9839841 locus. The populations are CD (788 males), 58C (752 males), and NBS (720 males). Note the
higher spread of the data points in CD.
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database, a Fisher’s exact test at evidence level three
gives P <1 0
-8. There are consistent disease associations
for 22 of the 28 identified instances, and one can reject
the null hypothesis that the observed associations are
random.
A permutation test
Another way to assess the significance of the stringent
test associations is via a permutation test. By switching
the labels of cases and controls with probability 0.5 and
applying the stringent test conditions, one can test the
null hypothesis that the distribution among cases rela-
tive to controls is the same as the distribution of con-
trols relative to cases.
In order to perform this test without manually check-
ing for homology, I limit the analysis to associations in
regions of at least 90% homology identified by the seg-
mental duplication database. SNPs in the MHC region
for T1D are excluded. With those limitations, there are
16 SNP/disease pairs satisfying the original stringent
test. Switching the labels of cases and controls for each
disease and SNP yields five qualifying SNP/disease pairs.
Based on this information, it is possible to approxi-
mate the permutation test distribution as a binomial dis-
tribution with N = 21 and a probability of 0.5. The
probability p that one would observe at least 16 associa-
tions under such a distribution is 0.013, allowing us to
reject the null hypothesis.
The relaxed filter
Seventeen stringent-filter SNPs with homology sufficient
to satisfy the segmental duplication database constraints
are also returned by the relaxed filter. 65 additional
instances covering 50 distinct SNPs survive the relaxed
filter. Four of these SNPs are among those identified
(for other diseases) using the stringent filters. Four addi-
tional SNPs are distinct from those identified by the
stringent test, but reside in the same duplicons as SNPs
from the stringent test. This data is summarized in
Table 7. P values for these associations are given in
Tables S2 and S3 in Additional file 1.
By design, the gene associations identified solely by the
relaxed filter may include false positives. Nevertheless,
several of these associations appear to be plausible for
the disease(s), and are promising candidates for further
study.
The region containing rs10502407 in chromosome 18
has known associations with bipolar disorder. GNAL,
and possibly other genes in this region, are subject to
epigenetic regulation, and constitute potential suscept-
ibility genes for BD and schizophrenia [137].
rs3858741 is identified as a gene conversion locus for
BD, CD and HT and rs9551988 is associated with T2D.
These two SNPs are within the same duplicon. The dis-
cussion of rs9551988 for the stringent filter analysis cov-
ers the BD, HT, and T2D associations. The NO pathway
also appears to be important for CD [138,139].
ALG10B is associated with HT in the stringent filter.
The association with CAD in the relaxed filter can also
be attributed to elongated QT intervals, as can the asso-
ciation with T1D [140]. ALG10B also appears to modu-
late K
+ current in neurons [141], making the link to BD
plausible. rs11053044 is identified as a gene conversion
locus in T2D; rs11053044 falls within the ALG10 dupli-
con. Elongated QT intervals are also observed in T2D
[142]. Variants of the pore-forming alpha-subunit potas-
sium channel gene KCNQ1 are associated with reduced
insulin secretion and T2D [143], and with forms of the
long QT-syndrome [143]. VPS35 is associated with BD
and CD. VPS35 appears to regulate Wnt signaling [144].
Wnt signaling is important for the proper structure of
the absorptive epithelium of the small intestine [145], a
plausible link with CD. The Wnt pathway is also asso-
ciated with BD [146].
The SNP rs9624808 is identified in T1D by the relaxed
test; rs9624808 is in same duplicon as rs4988327. LRP5
has been identified as a susceptibility locus for T1D
[147,148].
The SNP rs1291361 associates HTR7 and HEBP1 with
BD. HTR7 is a serotonin receptor that mediates impul-
sive behavior [149], and appears to have variants asso-
ciated with schizophrenia [150]. HEBP1 appears to
function in the brain’s response to oxidative stress [151].
PARP4, associated with T2D, is a DNA repair mole-
cule involved in nick sensing [152].
ROCK2, associated with CAD, HT, RA, and T1D, is
involved in various functions including actin cytoskeleton
Table 6 Comparison of the stringent and mock tests
Strength of evidence
Test 6 ≥5 ≥4 ≥3 ≥2 ≥10
Mock (/70) 6 (4) 6 (4) 7 (5) 11 (8) 13 (9) 16 (11) 84 (59)
Stringent (/28) 21 (6) 36 (10) 54 (15) 79 (22) 79 (22) 79 (22) 21 (6)
(/16) 31 (5) 50 (8) 62.5 (10) 87.5 (14) 87.5 (14) 87.5 (14) 12.5 (2)
Percentage (count) of SNPs with evidence in the various categories for the mock and stringent tests. The second row for the stringent test limits the analysis to
SNPs belonging to a duplicon in the segmental duplication database.
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way has been associated with CAD and HT [153].
DHFR, associated with T1D, converts dihydrofolate
into tetrahydrofolate, a necessary step for the de-novo
synthesis of purines. See Figure 4 and the discussion of
rs9378249, which is also associated with T1D by the
stringent filter.
XCL1 and XCL2 are associated with RA. XCL1 is pro-
duced by T cells in RA [154]. XCL1 and XCL2 regulate
the movement of cells expressing XCR1 [155], which is
upregulated in synovial fluid in RA [156]. The UGT1A
molecules, associated with BD, are responsible for meta-
bolizing and/or eliminating a variety of chemicals,
including mutagens and toxins [157].
CYP3A4, associated with RA, is involved in vitamin D
metabolism [158].
PDSS1 is associated with CAD and BD by the relaxed
filter. A germ-line mutation in PDSS1 was identified in
two siblings with cardiac disease and mental retardation
associated with coenzyme Q10 deficiency [159].
The no-call-only filter
Seventeen stringent-filter associations meet the no-call-
only filter condition on the p value; see the pn column
of Table S1 in Additional file 1. (Ten of these also
satisfy the homology requirements of the no-call-only
filter.) Eight relaxed-filter associations meet the no-
call-only filter condition; see the pn column of Tables
S2 and S3 in Additional file 1. Table 8 shows the
remaining 50 associations covering 37 distinct SNPs.
One of these SNPs (rs4471699) is among those identi-
fied (for other diseases) using the stringent filter. Nine
of these SNPs are among those identified (for other
diseases) using the relaxed filter. This data is summar-
ized in Table 8.
Beyond the SNPs already identified by the relaxed fil-
ter, the following no-call-only filter associations appear
to be promising candidates for future study.
SULT1A3 in BD and T2D. Impaired sulfation has
been linked with various neurological diseases [28,160].
Sulfoconjugation of monoamines via SULT1A3 occurs
within the brain, and could represent an important
detoxification pathway [28,161]. SULT1A3 is important
Table 7 Additional SNPs identified using the relaxed filter
SNP Disease(s) Characterized genes in duplicons
rs10147986 CD (40 duplicons)
rs10502407 BD [CIDEA]
rs10896468 CAD OR8U8, OR5M8
rs11010995 RA -
rs11028186 RA ALG1L, ASNS, [ZNF195], [FAM86B2],
[DEFB10P1], [DEFA5], [ZFYVE20]
rs11053044 T2D ALG10, ALG10B





rs12256867 T2D ZNF33A, ZNF37A, ZNF33B, ZNF37B, [ZNF25]
rs12413153 CAD DDX18, BTBD15, WDR22, [IBRDC2]
rs1291361 BD HTR7, HTR7P, [HEBP1]
rs1404223 CAD -
rs17080801 T2D PARP4, TPTE2








rs2236014 BD MTRF1L, [FBX05]
rs2515832 RA MAGEA12, CSAG1, MAGEA2, MAGEA3, TRAG3,
[MAGEA6]
rs2523544 T1D DHFRP2, DHFRL1, DHFR, PSMA8, [HLA-B],
[MSH3], [NSUN3]
rs2617729 CD, T2D ZNF761, ZNF765, ZNF813, [ZNF331]
rs330201 CAD MRPL10, [LRRC46], [OSBPL7]
rs3858741 BD, CD, HT PSPC1, [TUBA3C]
rs4318932 CD TYW1, TYW1B, [STAG3L4]
rs4453734 CAD, RA -
rs4473816 RA [GSPT2]
rs4532803 BD, HT ELA3A, ELA3B, [HSPC157]
rs4545817 BD ALG1, FAM86A, [COL6A4P2]
rs4881702 BD -
rs500192 BD, T1D TBL1XR1
rs5946541 BD [BAGE]
rs6427130 RA XCL1, XCL2
rs6463213 BD, T2D RBAK, RNF216L, XKR8
rs6744284 BD UGT1A3 -UGT1A10
rs6945984 RA CYP3A4, CYP3A7, [CYP3A5]




rs940331 T2D [ZNF735], [ZNF716]
rs9551988 T2D PSPC1, [TUBA3C]
rs9624808 T1D LRP5, LRP5L
rs9665670 BD, CAD [PDSS1]
rs9775226 CD, HT (40 duplicons)










RA GUSBL1, GUSBL2, SMA4, GUSBP1, [RGL4]
Genes in square brackets are outside the duplicons, but a duplicon is at most
30 kb upstream of the gene. Genes for two SNPs having 40 duplicons each
are omitted.
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Page 17 of 29for the degradation of dopamine in neurons [162], and
dopamine dysregulation has been linked with both BD
[163] and T2D [164].
TRIM48 and TRIM53 in BD, CD, and T2D. TRIM
proteins such as TRIM48 are thought to function during
the cellular response to viral infection [165].
CENPI in BD, CAD, HT, T1D, and T2D. CENPI is
located on the X chromosome, and is essential for
proper segregation during mitosis [166]. Disruption of
CENPI results in daughter cells having extra/missing
chromosomes [166].
HCCA2 (also known as MOB2) in RA and T1D.
HCCA2 appears to be important for proper segregation
during mitosis [167,168].
MYPT2 in HT. MYPT2 is expressed in the heart and
skeletal muscle where it dephosphorylates myosin and is
involved in muscle contraction [169,170]. Note that the
matching duplicon is on the Y chromosome, meaning
that somatic gene conversion could only happen in
males.
GPC5 in RA. GPC5 expression appears to be reduced
in arthritis [171] and GPC5 is located within a quantita-
tive trait locus for arthritis [172]. A SNP within GPC5
appears to be significant for parovirus-induced arthritis
[173]. Polymorphisms in GPC5 also appear to be asso-
ciated with the response of multiple-sclerosis patients to
interferon beta therapy [174], and GPC5 appears to be a
risk factor in multiple sclerosis [175].
HSD17B7 in HT. HSD17B7 catalyzes the conversion
of estrone to estradiol [176], and also is involved in cho-
lesterol biosynthesis [177]. Estradiol treatment lowers
blood pressure in hypertension [178-181]. Disruption of
HSD17B7 could lower endogenous estradiol concentra-
tions leading to an increase in blood pressure.
DPY19L2 in BD. In C. elegans, the DPY19 gene is
required to properly polarize and orient migrating neu-
roblasts during development [182].
ITGB2 in RA. The ITGB2 gene encodes the CD18
adhesion molecule present on several kinds of immune
cells. CD18 expression is upregulated in macrophages
and T-cells in the peripheral blood and synovial fluid of
RA patients [183,184].
Cluster plot artifacts
The 58C DNA samples were obtained from cell lines,
while the other samples (including the NBS control
sample) were obtained directly from blood cells [11].
Genomewide, the samples were statistically similar [11].
Nevertheless, it is conceivable that certain SNPs are sys-
tematically affected by the procedures used to establish
Table 8 Additional SNPs identified using the no-call-only
filter
SNP Disease(s) Characterized genes in duplicons
rs10238378 BD -
rs10485575 BD SNX5, ANO4
rs10768666 RA HCCA2, KRTAP5-8, KRTAP5-3, [KRTAP5-2],
[KRTAP5-1], [KRTAP5-5], [KRTAP5-9],
[KRTAP5-10],
rs10811497 BD IFNA4, IFNA7, IFNA10, IFNA14, IFNA16,
IFNA17, IFNA21, [IFNW1]
rs10896468 BD, CD, T2D OR8U8, OR5M8, [OR5M3], [OR5M9]
rs11228904 BD, HT, T1D TRIM48, TRIM53
rs11583656 HT MYPT2, [UBE2T]
rs1191684 BD [PAX8]
rs12428824 BD ENPP3, CTAGE4, CTAGE6, [OR2A7],
[OR2A20P], [OR2A4]
rs1421867 T1D -
rs1708080l BD, HT PARP4, TPTE2
rs17310770 T2D ROPN1, ROPN1B, CCDC14
rs17423694 HT [NBPF11]
rs17636964 BD, RA, T2D IPMK
rs1809667 T1D HCCA2, KRTAP5-2, KRTAP5-8, KRTAP5-3,
KRTAP5-10, KRTAP5-11, KRTAP5-7, [KRTAP5-
1], [DUSP8], [KRTAP5-5], [KRTAP5-9]
rs1819829 HT CES7, [CES1]
rs1820450 RA GPC5, [GOLGA8B]
rs1868584 BD ROCK2, CGGBP1, [ZNF654]
rs193017l T1D PCDH15
rs2039945 T2D -
rs2804672 HT HSD17B7, HSD17B7P2, CDC10L
rs3864439 BD DPY19L2, DPY19L2P1, DPY19L2P4,
[DPY19L1], [STEAP1]
rs4236384 RA SLC29A4, TNRC18
rs4318932 T2D TYW1, TYW1B, [STAG3L4]
rs4471699 BD, T2D SULT1A3, GIYD2, BOLA2, IMAA, CORO1A,
MLAS, SMG1, [UQCRC2], [NPIPL3]
rs4532803 CAD ELA3A, ELA3B, [HSPC157]
rs4545817 HT ALG1, FAM86A, [COL6A4P2]
rs584630 BD ZNF33A, ZNF33B, ZNF37A, ZNF37B, [ZNF25]
rs649483l RA FMN1
rs6510085 RA ZNF419, ZNF773, [ZNF772], [ZNF549]
rs651263l CAD -
rs731999l BD, CAD, HT,
T1D, T2D
CENPI








CD, BD GUSBL1, GUSBL2, SMA4, GUSBP1, [RGL4]
Genes in square brackets are outside the duplicons, but a duplicon is at most
30 kb upstream of the gene.
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at a SNP in the 58C population could make other popu-
lations appear to have high no-call rates at the SNP
relative to the combined controls. A significant differ-
ence between the 58C and NBS populations in cluster
positions for a SNP could be an indicator of such a bias.
At the same time, one cannot exclude the possibility
that the reasons for this bias may themselves be related
to gene conversion. For example, a cell that has under-
gone a conversion-induced mutation at a locus may not
be viable as a cell-line founder, meaning that only cells
with unmutated sequence at that locus will be present
in the cell-line samples.
A small number of individuals in the WTCCC data
generated outlying low-intensity points at multiple loci
in the CAD/RA/NBS cohorts, a probable artifact of dif-
ferent procedures for those cohorts [11]. High no-call
rates can also occur at a locus with copy number varia-
tion, where there are typically more than three clusters.
I therefore visually examined all cluster plots for SNPs
identified by the various filters, looking for clear exam-
ples of any of these three patterns.
The results are summarized in Table 9. For the strin-
gent filter rows labeled with a 58C disparity, the no-call
rate for 58C is less than one third of that for NBS. Four
of the seven stringent filter SNPs (rs12070036,
rs12381130, SNP_A-1797773, rs9257223) have signifi-
cantly higher no-call rates than the NBS population
alone (P < 0.005 for a one-sided chi-squared test). The
remaining three SNPs have no-call rates that are not
significantly difierent from the NBS population (P >
0.05). The P value for the stringent filter comparison
with the mock study remains below 10
-8 at evidence
level three even if all stringent filter SNPs in Table 9 are
excluded.
The SNP rs7761068 was considered in Figure 5 for the
analysis of rs9378249. The proportion of low-intensity
individuals at rs7761068 does not segregate with the
RA, CAD and NBS populations, and the 58C and NBS
populations have similar intensity distributions, suggest-
ing that the observed effect at rs7761068 is not
artifactual.
Since each cohort has a different proportion of males,
a duplicon on a sex chromosome could skew the cluster
plot results in a population specific way. Such skew is
clear for rs9839841, where a duplicon is on the Y chro-
mosome, and where 94% of the no-calls in CD are for
males. Measurements of the male proportion of no-calls
for all of the other stringent filter SNPs were close to
the proportions in the population as a whole (data not
shown). This observation excludes the possibility that a
probe sequence for these SNPs is absent from the refer-
ence human genome yet occurs frequently in the popu-
lation on a sex chromosome.
Linkage
In the present study, concordant observations at sev-
eral adjacent SNPs were not expected [10], and the
analysis did not require such observations. Looking at
the 28 SNPs identified by the stringent filter in Tables
2 and 3 retrospectively, one can look for evidence of
linkage in the form of a significantly increased no-call
rate at SNPs adjacent to the target SNP. Evidence of
linkage at the 28 loci, within the SNP resolution avail-
able on the microarray platform, is summarized in
Table 10.
These linkage results demonstrate that strong linkage
is unusual, and that when it occurs, linkage is typically
limited to one neighboring SNP. These results also sug-
gest that linkage is more common in BD and HT than
in other conditions.
Table 9 SNPs with anomalous cluster plots
Filter SNP Disease(s) Cluster plot
feature
Stringent, relaxed rs10502407 CAD, T2D,
BD
58C disparity
Stringent rs11010908 T2D 58C disparity
Stringent rs12070036 BD 58C disparity
Stringent rs12381130 T1D 58C disparity
Stringent rs295470 CAD 58C disparity
Stringent, relaxed SNP_A-
1797773
T2D, BD, CD 58C disparity
Stringent (MHC in
T1D)
rs9257223 T1D 58C disparity
Relaxed rs11028186 RA 58C disparity
Relaxed rs12256867 T2D 58C disparity
Relaxed rs1404223 CAD 58C disparity
Relaxed rs17230081 T2D 58C disparity
Relaxed rs1842055 CAD 58C disparity
Relaxed rs330201 CAD 58C disparity
Relaxed, no-call rs4318932 T2D NBS/CAD/RA
disparity
Relaxed rs4473816 RA 58C disparity
Relaxed rs7259082 CAD 58C disparity




No-call rs10238378 BD 58C disparity
No-call rs10485575 BD 58C disparity
No-call rs10811497 BD 58C disparity
No-call rs12428824 BD 58C disparity
No-call rs1421867 T1D more than 3
clusters
No-call rs1819829 HT NBS/CAD/RA
disparity
No-call rs2039945 T2D 58C disparity
No-call rs2804672 HT NBS/CAD/RA
disparity
No-call rs6512631 CAD 58C disparity
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While the filters discussed previously are designed to
identify gene conversion, it is possible that they also
capture cases of somatic deletion. Somatic deletion at a
SNP locus would be indistinguishable from somatic con-
version within the flanking sequence of the SNP. Look-
ing at the stringent filter results, approximately half of
the loci have pairs of duplicons within a few megabases
of each other on the same chromosome. This pattern
could lead to deletions through gene conversion, impro-
per recombination, or due to removal of sequence frag-
ments forming hairpin-like structures [185]. Somatic
duplication is also possible. For rs12381130 and
rs11010908, there is no disease-related gene within any
of the duplicons, while disease-related genes do occur
between duplicons. (The LRP5 gene resides on the chro-
mosome 11 interval for rs12381130, and the ANKRD26
gene resides on the chromosome 10 interval for
rs11010908.) For rs9378249, the data suggest that there
is a somatic deletion of the DHFRP2 pseudogene.
There is another kind of deletion that could give rise
to results that might appear like gene conversion. Con-
sider a SNP locus in which there exists a duplicon hav-
ing 100% sequence identity in the flanking sequence.
This duplicon would add to the signal of one of the
alleles at the SNP locus.(Cross-hybridization with less
that 100% identity is possible, but is ignored here.)
Assuming the duplicon is not polymorphic, this additive
signal would be consistent across individuals. The posi-
tions of the clusters would be different from a situation
without such a duplicon, but AA/AB/BB clusters would
still be able to be differentiated from one another.
Imagine a disease associated phenomenon in which
there is increased deletion of the duplicon (but not the
SNP region) due to improper recombination. In such a
case, there would be a bias towards a loss of signal for
the allele that is present in the non-polymorphic dupli-
con. This is the opposite bias to what one expects from
gene conversion of the SNP region by its duplicon
(although as discussed in Additional file 1, for conversion
of major to minor alleles, such a bias is still possible).
To investigate this possibility, I re-examined the
results of the stringent filter to identify cases where
there is (a) 100% identity of the duplicon within the
SNP’s flanking sequence, and (b) a change in the allele
distribution away from the allele in the duplicon. There
is one such SNP, namely rs9551988, that accounts for
three of the five observations (Table S1) where the allele
frequency changes away from the allele in the non-poly-
morphic duplicon. Given the additional information that
the duplicons for rs9551988 are 500 kb away from each
other on the same chromosome and in the same orien-
tation, it is reasonable to infer that deletion is the likely
explanation for the results observed at this locus.
Now imagine a disease associated phenomenon in
which there is increased deletion of the SNP region (but
not the non-polymorphic duplicon) due to improper
recombination. In such a case, there would be a bias
towards a relative loss of signal for the allele that is not
present in the non-polymorphic duplicon. This is the
same bias that one expects from gene conversion of
the SNP region by its duplicon. I therefore re-examined
the results of the stringent filter to identify cases where
there is (a) 100% identity of the duplicon within
the SNP’s flanking sequence, and (b) a change in the
allele distribution towards the allele in the duplicon.
There are four such cases, namely rs669980, rs935019,
SNP_A-1797773, and rs9839841. Of these, only
rs935019 represents a case with nearby aligned dupli-
cons on the same chromosome. For rs935019, variation
Table 10 Linkage between stringent-filter SNPs and adjacent SNPs
Stringent test SNP Disease Adjacent SNP P Comments
rs9551988 HT rs3858741 3.2 × 10
-12 1.1 kb away, within same duplicon
BD rs3858741 8.9 × 10
-8 (No linkage for CAD.)
rs9378249 BD rs2596477 3.7 × 10
-7 22 bp away, within same duplicon
HT rs2596477 6.0 × 10
-4
rs841245 HT rs12229182 2.5 × 10
-6 12 kb away, within same duplicon
rs841636 1.7 × 10
-5 12 kb away, within same duplicon
(No linkage at intervening SNP rs10842853)
SNP_A-1948953 BD rs9893203 5.4 × 10
-4 8.6 kb away
HT rs9893203 6.8 × 10
-4
rs11010908 T2D rs17561365 1.2 × 10
-3 3.2 kb away, within same duplicon
The P value corresponds to a one-sided chi-squared test for an increased no-call rate. P values for excluded SNPs were all above 2 × 10
-3.
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ments [65], suggesting that deletion is the most likely
explanation for this locus.
An additional example was observed during the exam-
ination of SNPs using BLAST to determine whether
they reside in a region with homology elsewhere in the
genome. rs2812 met the stringent filter conditions for
CAD except that it did not reside in a duplicated region.
Nevertheless, a 400 bp duplicon occurred both upstream
and downstream of rs2812, together spanning a 2 kb
region including the SNP. rs2812 is located within the
PECAM1 gene, which has previously been associated
with CAD [186-188]. Out of approximately 250 SNPs
that were examined in this way, rs2812 was the only
one for which this kind of duplication pattern was
observed. Nevertheless, the present study was not
designed to identify such patterns, and additional
longer-range (or inter-chromosomal) duplication that
increases the likelihood of sequence deletion may exist.
Known de-novo non-allelic conversion sites
Five pairs of genes have been identified as loci of
de-novo germ-line gene conversion between non-allelic
regions, leading to a disease phenotype [1]; see
Table 11. If these conversion events are frequent enough
t ob en o t i c e de v e ni nt h eg e r m l i n e ,t h e ns u c hl o c im a y
be likely to be sites of relatively frequent somatic con-
version. I therefore examine SNPs located in duplicons
related to these gene pairs to determine whether the
cluster plots support this hypothesis.
I consider all SNPs appearing in one of the two dupli-
cons shared by the two genes. Coverage is limited by
the resolution of the microarray. In fact, no SNPs are
available for the CYP21A1P/CYP21A2 genes. For the
SBDSP/SBDS pair, there are four almost-contiguous seg-
mental duplications in the segmental duplication data-
base, spanning just over 500 kb. I consider all SNPs in
all of the four duplicons. I visually inspected the cluster
plots for the SNPs in the corresponding duplicons. The
target pattern is one in which for every population
(including controls) there is a substantial number of
points between clusters. The results of the visual cluster
plot analysis are summarized in Table 12. The visual
analysis is supported by the WTCCC quality control
procedures: for seven of the nine identified SNPs (all
except rs6578592 and rs1465306) the SNP was excluded
for quality control reasons such as departure from HWE
in the control population. (One additional SNP,
rs1880278, was also excluded for quality control reasons
but did not show features predicted for gene
conversion.)
G i v e nt h es m a l ls a m p l es i z ea n ds p a r s ec o v e r a g eo f
the duplicons, the results of Table 12 are suggestive, but
far from definitive.
Disease-specific patterns
Based on the SCE data, RA was predicted to be a local
disease. Four SNPs that are associated with RA
(rs4988327, rs10768666, rs4236384, rs9976299) have
cluster plots in which RA alone has an increased num-
ber of no-calls. When other disease populations have
correlated behavior, the RA population sometimes
appears to remain close to the control population, as
exemplified in Figure 5. In contrast, no other disease
population has an associated SNP for which that popu-
lation alone has an increased no-call rate.
These results are broadly consistent with a view of RA
as a local disease, and of the remaining diseases as glo-
bal diseases. The distinction is not clear-cut, however,
since there are RA-associated SNPs with no-call beha-
vior that is similar across multiple diseases.
An alternative interpretation of the distinctness of
RA is based on the observation that lymphocytes may
be the initiators of RA pathogenesis. Since lymphocytes
are the cells being genotyped, lymphocyte-specific
autoimmune dynamics could amplify the signal attribu-
t a b l et op a t h o g e n i cm u t a t ions. For example, a muta-
tion in a T cell that leads to cell activation and
replication would substantially increase the population
of cells exhibiting the mutation. Of the four SNPs
showing RA-specific spread in the cluster plots,
rs9976299 is notable for being within the ITGB2 gene
which encodes the CD18 adhesion molecule. CD18
expression is upregulated in macrophages and T-cells
in the peripheral blood and synovial fluid of RA
patients [183,184].
Table 11 De-Novo conversion events in disease [1]
Disease Donor Acceptor
Atypical haemolytic uraemic syndrome CFHR1 CFH
Congenital adrenal hyperplasia CYP21A1P CYP21A2
Neural tube defects FOLR1P FOLR1
Hereditary persistence of fetal haemoglobin HBG2 HBG1
Shwachman-Diamond syndrome SBDSP SBDS
Table 12 Possible conversion in duplicons for genes







CFHR1/CFH 7 rs395998, rs413979
FOLR1P/FOLR1 5 rs1540087
HBG2/HBG1 3 rs6578592
SBDSP/SBDS 38 rs4717344, SNP_A-1849003,
rs4718487, rs1465306, rs2003206
Events are identified by visually inspecting cluster plots for all SNPs in the
region.
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SNPs. Three of these SNPs display similar linkage pat-
terns with neighboring SNPs for both BD and HT. These
factors suggest that BD and HT may have a common
ultimate cause that is different from the other five dis-
eases. A general similarity between HT and BD has pre-
viously been identified using a classification algorithm
over the same WTCCC data set [189]. Individuals with
BD have a more than twofold increased risk of HT [190].
Discussion
Based on prior data for loci such as IDS [3,4], disease
related genes were sought in one of several duplicons,
only one of which contains the identified SNP. For 8
out of the 28 stringent filter SNPs, the disease related
gene is on a duplicon not containing the SNP, empha-
sizing the importance of examining all duplicons. Such
genes would not be identified using a conventional asso-
ciation study.
Confounding factors could perturb cluster plots,
potentially leading to false associations. Loci that did
not meet the WTCCC quality control requirements
have been excluded. The WTCCC reports a disparity
between the NBS/RA/CAD cohorts and the other
cohorts for some SNPs [11]; such disparities are rare
among the SNPs meeting the filter conditions (Table 9).
Additional quality control issues not identified by the
WTCCC are possible. Nevertheless, it is hard to imagine
how a quality control artifact could lead to population-
specific effects that correlate with disease related genes.
Copy-number variation can be discounted as a general
explanation for the observed phenomena, since none of
the stringent test SNPs (and only one of the no-call
SNPs) showed more than three clusters. Further, few of
the stringent filter SNPs are within known CNV loci
(Additional file 1). Even if copy number variation was
the mechanism responsible for some of the present
results, the results would still be interesting as novel
cohort-specific associations.
The present paper provides support for the hypothesis
that many complex diseases are caused in part by
somatic mutation in regions with homology elsewhere
in the genome. Diseases such as cancer often display
gross karyotypic changes that could be due to improper
recombination between nonallelic homologous regions
in somatic tissue. Because detection of somatic muta-
tions is technically much more demanding than that of
germline mutations, somatic gene-conversion events in
cancer have probably been underestimated [1].
Some puzzling epidemiological features of autoim-
mune diseases are consistent with a somatic mutation
hypothesis. Association with viruses can be explained by
the mutagenic actions of those viruses. Associations of
autoimmune disease with higher latitudes has been
hypothesized to relate to lower vitamin D levels [191];
vitamin D is associated with lower rates of double-
strand breaks [192] and with protection from viral infec-
tions [193]. Complex inheritance patterns spanning mul-
tiple diseases would result from a common underlying
genetic susceptibility based on sequence homology,
combined with stochastic effects such as tissue-specific
viral infection.
In order to be identified as a conversion region in this
study, the region must contain a locus that is within the
SNP repertoire of the microarray chip. A substantial
amount of somatic gene conversion might affect loci
with alleles that are fixed in the population. If so, alter-
native platforms will be needed to detect such conver-
sion. It is likely that there is additional disease-specific
somatic gene conversion that the present study has not
detected even among the covered SNPs. Spread in the
cluster plots might not be apparent if a particular dis-
ease-causing somatic mutation was rare enough that the
perturbation was small relative to experimental
variation.
On the other hand, common gene conversion events
might preferentially include SNP loci. If a conversion
event is common in somatic tissues, it may also be rela-
tively common in the germ-line. If the germ-line event
is not deleterious, a polymorphism could result. The
consequences of somatic and germ-line changes are dif-
ferent, and a somatic mutation may cause disease where
ag e r m - l i n ec h a n g ed o e sn o t .F o re x a m p l e ,as o m a t i c
mutation may result in a novel protein that is immuno-
genic. Alternatively, some of the loci associated with a
conversion event may be phenotypically neutral, and
these may lead to polymorphisms as a result of partial
conversion events in the germ-line.
The phenotype of a somatic mutation is likely to be very
different from the phenotype of a germ-line mutation.
Outside of cancer, there is very little data about pheno-
types associated with somatic mutations. It is therefore
dificult to correlate the observations of this paper with
existing knowledge about somatic mutation. Correlations
with genomewide studies of disease associated polymorph-
isms are possible in principle. However, given the meth-
odologies used in those studies (for example, requiring
multiple concordant SNPs [11]), it is not expected that
correlations will be found given the absence of linkage dis-
equilibrium for gene conversion [10].
It may well be that somatic gene conversion is, in some
cases, a normal adaptive phenomenon. Such effects
might be detectable using SNP microarrays by examining
the intensity plots directly without employing a calling
algorithm. The quality control protocols of SNP array
studies typically exclude loci where the called allele fre-
quencies depart from HWE in the control population,
which would exclude loci for which somatic gene
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such loci, particularly those in duplicated regions.
The present report suggests that somatic gene conver-
sion is associated with mutations and genomic rearran-
gements that lead to disease. Working backwards, one
could generate hypotheses for further study by identify-
ing genomic regions with high degrees of homology that
contain disease-relevant genes. For example, the BRCA1
gene that is involved in DNA stability and repair path-
ways [194] itself contains a segmental duplication that
includes part of the gene and its promoter region
[195,196]. Some BRCA1-related cancers appear to be
caused by gene conversion events in individuals carrying
o n em u t a n tB R C A 1a l l e l e[ 1 9 7 ] .O n c eB R C A 1f u n c t i o n
is compromised, gene conversion and rearrangement at
other loci may become more frequent.
Gene conversion could be a cause of the disease pheno-
type, or it could alternatively be a side-effect of an underly-
ing disease-causing genetic disorder with no direct bearing
on the phenotype. The fact that disease associations are
found for most of the stringent filter SNPs is strongly sug-
gestive of a causative link in which the specific conversion
events are the proximate causes of the phenotype.
I have used the output of the Chiamo algorithm with-
out modification. Spread is inferred from a high number
of no-call results at a locus. While this method of infer-
ring spread appears to have been effective, more effec-
tive methods might be possible. Methods could measure
suitably defined ‘spread statistics’ given allele intensity
distributions for several populations.
T h es u c c e s so ft h ea n a l y s i s supports the hypothesis
suggested by the sister chromatid exchange studies that
DNA in lymphocytes undergoes similar transformations
to DNA in tissues affected by disease. In principle, it
may be possible to test for various somatic mutations
using a blood sample. Specialized microarrays could be
developed to detect specific sequences resulting from
common somatic mutations.
Several important questions remain. The present study
does not allow the quantification of risk associated with
any particular gene conversion locus. Even the identifi-
cation of which individuals have substantial conversion
at a locus is approximate. Locus-specific experimental
studies of conversion frequencies in health and disease
are needed.
The present study also does not quantify the degree of
conversion necessary to cause disease. In lymphocytes,
for example, mutations in a very small number of cells
could cause disease if those cells undergo clonal expan-
sion. In other tissues, many cells might need to be
mutated before tissue function is compromised. Stem
cell mutations (which may be relatively common due to
frequent mitosis) could lead to a regular inflow of
mutated cells.
Disease associations with a number of specific genes
have been suggested by the present work. Changes at
these loci in somatic tissues may represent the proxi-
mate cause of disease. Nevertheless, the ultimate cause
of disease is the factor that causes the DNA damage.
Environmental factors are likely to play a significant
role. The association of the folate-dependent thymine
nucleotide synthesis pathway with several diseases,
together with an increase in the frequency of SCEs
under methotrexate treatment [198], also suggests
another kind of ultimate cause in which impaired DNA
synthesis leads to homology-driven repair [199].
Conclusions
That somatic gene conversion may occur frequently has
been previously suggested, but progress has been ham-
pered by the technical difficulty of measuring somatic
gene conversion on a large scale [1]. The present study
is the first to use genome-scale SNP data to infer
somatic gene conversion loci in specific populations. For
more than 75% of the loci, genes within the locus
associate with the corresponding disease in a manner
consistent with known gene/disease associations.
Any single association identified in this report should
be considered tentative, and subject to experimental
confirmation. Nevertheless, taken together, the associa-
tions provide compelling evidence that somatic gene
conversion and/or somatic deletion at particular loci
influence each of the seven studied diseases. The techni-
ques developed are not specific to the WTCCC data,
and could be applied to other data sets to identify puta-
tive gene conversion for other diseases.
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